Metabolic disorders in vertically HIV-infected children: Future adults at risk for cardiovascular disease

Journal of Pediatric Endocrinology and Metabolism

Volumn 25, Issue 5-6, 2012, Pages 529-535

  Dapena, Marta ^a   Jiménez, Beatriz ^b   Noguera Julian, Antoni ^c   Soler Palacín, Pere ^a   Fortuny, Clàudia ^c   Lahoz, Rebeca ^c   Aracil, Francisco Javier ^b   Figueras, Concepción ^a   De José, María Isabel ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antiretroviral; Dyslipidemia; HIV; HIV associated lipodystrophy syndrome; Insulin resistance

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STAVUDINE; THYROID HORMONE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADOLESCENT; ARTICLE; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; CHILD; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOATROPHY; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MIXED INFECTION; MULTICENTER STUDY; PREVALENCE; RISK FACTOR; SCHOOL CHILD; THYROID HORMONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VERTICAL TRANSMISSION; ADULT; CARDIOVASCULAR DISEASE; DISEASE TRANSMISSION; DYSLIPIDEMIA; MULTIVARIATE ANALYSIS; STATISTICS;

ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; CHILD; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INSULIN RESISTANCE; MALE; METABOLIC DISEASES; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 84865639216     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2012-0005     Document Type: Article

References (34)

1. ViganòA, Cerini C, Pattarino G, Fasan S, Zuccotti GV. Metabolic complications associated with antiretroviral therapy in HIVinfected and HIV-exposed uninfected paediatric patients. Expert Opin Drug Saf 2010;9:431-45.
2. Aldrovandi GM, Lindsey JC, Jacobson DL, Zadzilka A, Sheeran E, et al., for the Pediatric AIDS Clinical Trials Group P1045 team. Morphologic and metabolic abnormalities in vertically HIVinfected children and youth. AIDS 2009;23:661-72.
3. Resino S, Micheloud D, Lorente R, Bellón BM, Navarro ML, et al. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy. HIV Med 2011;12:54-60.
4. Dimock D, Thomas V, Cushing A, Purdy JB, Worrell C, et al. Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood. Metabolism 2011;60;874-80.
5. ViganòA, Brambilla P, Pattarino G, Stucchi S, Fasan S, et al. Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children. Clin Drug Investig 2009;29:101-09.
6. Rhoads MP, Smith CJ, Tudor-Williams G, Kyd P, Walters S, et al. Effects of highly active antiretroviral therapy on paediatric metabolite levels. HIV Med 2006;7:16-24.
7. Tassiopoulos K, Williams PL, Seage III GR, Crain M, Oleske J, et al., for the International Maternal Pediatric Adolescent AIDS Clinical Trials 219C Team. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease Inhibitors, among perinatally HIV-infected children. J Acquir Immune Defic Syndr 2008;47:607-14.
8. Spolou V, Kanaka-Gantenbein C, Bathrellou I, Mora S, Mostrou G, et al. Monitoring of lipodystrophic and metabolic abnormalities in HIV-1 infected children on antiretroviral therapy. Hormones 2011;10:149-55.
9. Rhoads MP, Lanigan J, Smith CJ, Lyall EG. Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr 2011;57:404-12.
10. Guzmán-Fulgencio M, Micheloud D, Lorente R, Bellón JM, de JoséGomez MI, et al. Cardiovascular risk markers are increased in HIV-infected children with lipodystrophy syndrome. J Infect 2011;62:240-3.
11. Farley J, Gona P, Crain M, Cevia J, Oleske J, et al. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C. J Acquir Immune Defic Syndr 2005;38:480-7.
12. Yeste D, Carrascosa A. Obesity-related metabolic disorders in childhood and adolescence. An Pediatr (Barc) 2011;75:135. e1-9.
13. CDC Health disparities and inequalities request - United States, 2011. MMWR Morb Mortal Wkly Rep 2011;60(Suppl):73.
14. Resino S, Micheloud D, Larrú B, Bellón JM, León JA, et al. Spanish Group of Paediatric HIV Infection. Immunological recovery and metabolic disorders in severe immunodeficiency HIV type 1-infected children on highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2008;24:1477-84.
15. CDC 1994. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;43:1-10.
16. American Academy of Pediatrics. Cardiovascular risk reduction in high-risk pediatric populations. Pediatrics 2007;119: 618-21.
17. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, et al. Cardiovascular risk reduction in high-risk pediatric populations: a scientific statement from the American Heart Association Expert Panel. (Endorsed by the American Academy of Pediatrics). Circulation 2006;114:2710-38.
18. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, et al. IDF consensus Group. Metabolic syndrome in children and adolescents-an IDF consensus report. Pediatr Diabetes 2007;8:299-306.
19. Tresaco B, Bueno G, Pineda I, Moreno LA, Garagorri JM, et al. Homeostatic model assessment (HOMA) index cut-off values to identify the metabolic syndrome in children. J Physiol Biochem 2005;61:381-8.
20. Carrascosa Lezcano A, Fernández García JM, Fernández Ramos C, Fernández Longás A, López Siquero JP, et al. Grupo Colaborador Español. Spanish cross-sectional growth study 2008. Part II. Height, weight and body mass index values from birth to adulthood. An Pediatr (Barc) 2008;68:552-69.
21. WHO child growth standards and the identification of severe acute malnutrition in infants and children. A joint Statement by the World Health Organization and the United Nations Children ' s Fund. WHO, Unicef, 2009. Available at: http://www.who.int/nutrition/publications/severemalnutrition/ 9789241598163-eng.pdf, accessed 3 Aug 2011.
22. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004;18:1443-51.
23. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-16.
24. Hartman K, Verweel G, de Groot R, Hartwig NG. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006;25:427-31.
25. Brown TT, Glesby MJ. Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol 2011;20:11-21.
26. Jaquet D, Lévine M, Ortega-Rodriguez E, Faye A, Polak M, et al. Clinical and metabolic presentation of the lipodystrophic síndrome in HIV-infected children. AIDS 2000;14:2123-8.
27. Lee B, Aurpibul L, Sirisanthana V, Mangklabruks A, Sirisanthana T, et al. Low prevalence of insulin resistance among HIVinfected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand. HIV Medicine 2009;10:72-8.
28. ViganòA, Riboni S, Bianchi R, Cafarelli L, Vago T, et al. Thyroid dysfunction in antirretroviral treated children. Pediatr Infect Dis J 2004;23:235-9.
29. Park YJ, Lee YJ, Choi SI, Chun EJ, Jang HC, et al. Impact of subclinical hypothyroidism on the coronary artery disease in apparently healthy subjects. Eur J Endocrinol 2011;165:15-21.
30. Grapin M, Piroth L, Verges B, Sgro C, Mack G, et al. Increased prevalence of subclinical hypothyroidism in HIV patients treated with highly active antiretroviral therapy. AIDS 2000;14: 1070-2.
31. Tungsiripat M, O' Riordan MA, Storer N, Harrill D, Ganz J, et al. Subjective clinical lipodystrophy Assessment correlates with DEXA-measured limb fat. HIV Clin Trials 2009;10:314-9.
32. McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. AIDS 2004;18:1753-68.
33. Ross AC, McComsey GA. Cardiovascular disease risk in pediatric HIV: the need for population-specific guidelines. J Acquir Immune Defic Syndr 2011;57:351-4.
34. Soler-Palacín P, Ciria L, Polo R, Couceiro JA, de JoséMI, et al; Study Group for the Pediatric HIV-patient for the National AIDS Plan (SPNS). Recomendaciones CEVIHP/SEIP/AEP/SPNS parael seguimiento del paciente pediátrico infectado por el Virus de la Inmunodeficiencia Humana (VIH). Sanidad, June 2009. Available at: http://www.mspsi.gob.es/ciudadanos/ enfLesiones/enfTransmisibles/sida/publicaciones/profSanitarios/ recoSeguimiento-PediatricoVIHJunio09.pdf, accessed 3 Aug 2011.